AI in Clinical Trials: What Are the Latest Trends?

The use of AI in clinical trials is transforming precision medicine, genomics, real-world evidence, decentralized trials and predictive analytics. Advances in these areas have increased the need for specialist talent to provide human oversight, from clinical operations and regulatory affairs talent to data scientists and biostatisticians. Organizations now need people who can direct, validate, and act on AI outputs to combat challenges such as data quality, algorithmic bias, and regulatory uncertainty.

Key Takeaways:

AI-assisted recruitment tools are improving clinical trial enrollment by 65% at a time when clinical trials are facing recruitment delays affecting 80% of studies.
Research has indicated that AI can expedite the clinical trial process from recruitment and protocol optimization to data analysis and risk prediction, though human oversight and guidance are still required to keep its use in a relevant context and within ethical boundaries.
Rising protocol complexity and trial failure rates have expanded the use of AI in precision medicine, with emerging trends including the use of AI for protocol risk assessment, predictive recruitment modeling, integration of historical data, and cloud-based feasibility tools.
Human oversight is still critical for regulatory credibility and for genuine human, cognitive engagement with AI outputs, creating significant demand for specialists to meet these increasingly important needs.

How is AI Being Used in Clinical Trials?

AI in clinical trials has a multitude of uses, each providing greater efficiency when implemented effectively. Clinical trials are facing mounting challenges, including recruitment delays affecting 80% of studies, escalating costs exceeding $200 billion annually in pharmaceutical R&D, success rates below 12% and data quality issues affecting 50% of datasets. AI in clinical trials is being treated as a transformative solution.

If the shifting approach to clinical trials could be summarized, it would be that companies are moving from a reactive, tediously manual approach to an automated, predictive one, still reliant on human oversight to avoid biases and include context.

AI is currently being implemented in clinical trials for:

Protocol and trial design: AI can choose the eligibility criteria, predict trial success, and build more efficient study designs before the trial starts.
Recruitment: Research has indicated that AI-assisted recruitment tools improved enrollment by 65% and cut trial timelines by 30-50%, making them a valuable asset for screening, cohort identification, eligibility extraction, and retention workflows.
Data analysis: AI can expedite data analysis through processing imaging, HER, wearable, and trial data to detect patterns and support overall analysis without lengthy manual work.
Risk prediction: AI models are being more frequently implemented to estimate safety, efficacy, and operational risks (e.g., adverse events, trial failure, recruitment issues).

How is AI Transforming Clinical Trial Design and Management?

The aim of most AI use in clinical trial design and management is to streamline protocol design, automate data management, and to reduce overall timelines and costs.

Clinical trials and medication development rely heavily on recruitment efforts, which can result in failure for the trial if participants are not sourced quickly enough. AI can help to find those who would get the most value out of taking part in clinical research, analyzing data and pinpointing the best sites for recruitment.

A recurrent issue with traditional clinical trials, particularly those intended for smaller and diverse patient groups, is that they lack the analytical sophistication and speed required, combined with difficulty tracking participants’ adherence to protocols. AI has been shown to improve protocol design alongside patient recruitment, leading to higher chances of trial success.

Analysis revealed significant AI benefits:

Patient recruitment tools improved enrollment rates by 65%.
Predictive analytics models achieved 85% accuracy in forecasting trial outcomes.
AI integration accelerated trial timelines by 30-50% while reducing costs by up to 40%.

In short, AI can expedite the clinical trial process from recruitment and protocol optimization to data analysis and risk prediction, though human oversight and guidance are still required to keep its use in relevant context and within ethical boundaries.

What Are the Latest Trends in AI Applications for Clinical Trials?

There has been a marked increase in AI-related trials over time, with recent growth in reference to machine learning, deep learning, chatbots, GPTs, and large language models, with the United States accounting for the largest number of AI-related trials.

Rising protocol complexity and trial failure rates have expanded the use of AI in precision medicine, with emerging trends including the use of AI for protocol risk assessment, predictive recruitment modeling, integration of historical data, and cloud-based feasibility tools.

Genomic profiling analyzed by AI has also identified actionable mutations in far more tumors (67% vs. 33% for smaller panels), improving matching to targeted therapies. Subsequently, demand for biomarker scientists and precision oncology specialists has increased due to a need for greater understanding of companion-diagnostic pathways.

AI and machine learning in clinical trials is also being used to identify complex biomarkers that predict a patient’s response, with multi-omic data (genomics, proteomics, imaging, HER) now integrated via AI, aiding drug target identification and treatment-response to expedite the drug development process. Hybrid and decentralized trials are also becoming more common clinical trial trends, utilizing virtual consent, tele-visits, remote assessments, and home-based data to cut down trial duration and reduce dropouts. Subsequently, hybrid professionals that understand both the science and advanced data systems are essential.

Another up-and-coming element is AI-curated real-world evidence (RWE) to build synthetic control arms, which is being used in oncology and rare-disease contexts to reduce control-group size and costs.

The FDA’s “Enhancing Participation in Clinical Trials” recommends that sponsors broaden eligibility criteria, optimize trial sites, and monitor enrollment to increase representation, which is a gap AI has filled with predictive analytics, with models flagging geographic and demographic coverage gaps before enrollment opens.

AI in clinical trials is moving from experimentation into core infrastructure, which has meant that an organization’s digital fluency is being measured by its specialized talent rather than generalist AI skills.

Why Human Expertise Remains Essential in AI-Enabled Clinical Research

There can be a temptation when it comes to AI in clinical trials to view AI as processing data at a scale no team could match manually. The benefits of AI in clinical trials are already well established, from faster timelines and better data quality to lower burden on sites and patients.

However, industry leaders are pointing towards one caveat — these gains are only durable when AI augments expert judgment rather than replacing it. Human oversight is still critical for regulatory credibility and the genuine human, cognitive engagement with AI outputs. This has created significant demand for specialists to meet these increasingly important needs:

Clinical operations: When AI flags risks (e.g., performance issues, enrollment gaps, safety signals), clinical operations professionals are critical in translating these into real trial decisions using operational judgment AI simply doesn’t have on its own.
Regulatory affairs: With AI tools moving into submissions and monitoring, regulators are clear that human accountability is a non-negotiable, as AI should be implemented to strengthen oversight rather than bypass it, requiring regulatory affairs talent to oversee the application of AI.
Data scientists: Data scientists are necessary to validate tools for specific clinical contexts and govern with meaningful oversight, and their critical role is leading to considerable skill gaps at a time when data scientist employment is projected to grow significantly.
Biostatisticians: Bringing statistical judgment to AI-generated risk-benefit and safety predictions before approving, modifying, or rejecting them is essential. This human oversight model for biostatisticians would include reviewing AI predictions and considering data integrity and clinical relevance (particularly important from a patient safety and trial integrity perspective).
Medical experts: Clinical knowledge is paramount in countering a key weakness of AI in clinical trials – generating confident output that isn’t always factually accurate – by translating complex AI-generated data into decisions without the risk of inaccurate information.
Validation professionals: By building the oversight layer that covers third-party AI models, validation professionals are increasingly important from a regulation perspective, ensuring learning models and automated systems comply and produce accurate data in line with regulatory bodies.

All of the in-demand roles driving clinical trial technology trends ensure that AI systems augment rather than replace human expertise, utilizing hybrid scientific, technical, and regulatory expertise to integrate human oversight.

Sourcing these professionals can be extremely difficult due to high demand, particularly with the pace of technological advancement in clinical trials. At Redbock, we specialize in sourcing hybrid professionals across quality, clinical, regulatory, and engineering, and can find the specialized expertise you need to be at the forefront of innovation.

What Are the Main Challenges of Using AI in Clinical Trials?

The use of AI in clinical trials isn’t without challenges and potential barriers. One key concern is AI’s tendency to confidently produce factually incorrect information, which for clinical trials where accuracy, reliability, and regulation are paramount is a significant challenge.

Research has also indicated that AI in clinical trials has resulted in selection bias, limited prospective studies, and data quality issues even with the potential to transform trials. Additionally, significant implementation barriers are another issue, including data interoperability challenges, regulatory uncertainty, algorithmic bias concerns, and limited stakeholder trust.

It’s clear that the use of AI in clinical trials needs parameters and oversight to overcome these challenges, including evidence, governance, cyber, interoperability, and operational readiness. The ecosystems that can help AI to thrive in clinical trials need to be built on trusted, privacy-first and preserving evidence systems with oversight to function effectively and ethically.

Human expertise is the key to unearthing AI’s potential in clinical trials.

Why Partner with Redbock?

Redbock is a leading life science consulting firm, utilizing a network of 600+ active consultants with deep domain expertise and 24+ years of experience resourcing quality, clinical, regulatory and engineering talent.

If you’re struggling to source specialists in the hybrid, hard-to-fill roles that the AI clinical trial landscape demands, get in touch with Redbock today to build a team that can keep pace with AI-enabled research.